002437.SHE Harbin Gloria Pharmaceuticals
- Market cap
- CNY 6.51B
- P/E
- 17.2x
- P/B
- 2.53x
- ROE
- 12.9%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002437.SHE undervalued?
Graham number002437.SHE trades 38.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harbin Gloria Pharmaceuticals fundamental analysis
No fundamental analysis for Harbin Gloria Pharmaceuticals yet.
Harbin Gloria Pharmaceuticals stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler…
Full company profileHarbin Gloria Pharmaceuticals financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harbin Gloria Pharmaceuticals annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.98B | 3.04B | 5.48B | 5.05B | 3.05B | 3.15B | 3.11B | 2.63B | 2.44B | 2.14B | 1.90B |
| Gross Profit | 1.74B | 2.14B | 4.08B | 3.71B | 2.20B | 2.31B | 1.75B | 1.53B | 1.30B | 968M | 888M |
| Operating Income | 775M | 343M | 172M | -2.47B | 579M | 95.9M | -270M | 175M | 285M | 269M | 329M |
| EBITDA | 1.12B | 717M | 520M | -2.27B | 807M | 296M | -58.6M | 323M | 397M | 503M | 376M |
| Net Income | 717M | 310M | 126M | -2.66B | 400M | 45.0M | -291M | 120M | 233M | 377M | 331M |
| EPS | 0.33 | 0.14 | 0.06 | -1.21 | 0.18 | 0.02 | -0.13 | 0.05 | 0.10 | 0.17 | 0.15 |
| Balance Sheet | |||||||||||
| Total Assets | 8.67B | 9.06B | 9.48B | 6.41B | 4.52B | 4.70B | 4.07B | 3.15B | 2.83B | 3.13B | 3.38B |
| Total Liabilities | 4.62B | 4.81B | 5.08B | 4.82B | 2.58B | 2.72B | 2.37B | 1.44B | 852M | 825M | 798M |
| Shareholders' Equity | 3.96B | 4.17B | 4.32B | 1.52B | 1.85B | 1.89B | 1.63B | 1.66B | 1.95B | 2.29B | 2.56B |
| Cash & Short-term Investments | 1.20B | 962M | 1.31B | 1.31B | 895M | 1.50B | 1.29B | 711M | 512M | 396M | 492M |
| Total Debt | 3.72B | 3.57B | 3.12B | 2.68B | 1.35B | 1.56B | 1.45B | 676M | 1.95M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.04B | 652M | 1.16B | 610M | 12.8M | 274M | 262M | 274M | 411M | 273M | - |
| Capital Expenditure | 185M | 195M | 104M | 48.4M | 43.7M | 34.5M | 33.0M | 29.6M | 62.9M | 23.8M | 17.6M |
| Free Cash Flow | 855M | 457M | 1.06B | 562M | -30.9M | 240M | 229M | 245M | 348M | 250M | 360M |
| Ratios | |||||||||||
| ROE | 18.1% | 7.4% | 2.9% | -175.0% | 21.7% | 2.4% | -17.9% | 7.2% | 11.9% | 16.4% | 12.9% |
| ROA | 8.3% | 3.4% | 1.3% | -41.5% | 8.9% | 1.0% | -7.2% | 3.8% | 8.2% | 12.0% | 9.8% |
| Net Profit Margin | 24.0% | 10.2% | 2.3% | -52.7% | 13.1% | 1.4% | -9.4% | 4.6% | 9.5% | 17.6% | 17.4% |
| Debt to Equity | 0.94x | 0.86x | 0.72x | 1.76x | 0.73x | 0.82x | 0.89x | 0.41x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harbin Gloria Pharmaceuticals dividends
- Dividend yield
- 0.02%
- Forward dividend
- -
- Payout ratio
- 0.3%
- Ex-dividend date
- Jun 28, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.21M | 0.00 | 0.3% |
| 2024 | CNY 9.36M | 0.00 | 4.0% |
| 2023 | CNY 43.8M | 0.02 | 36.4% |
| 2022 | CNY 68.8M | 0.03 | - |
| 2021 | CNY 70.9M | 0.03 | 157.5% |
| 2020 | CNY 134M | 0.06 | 33.6% |
| 2019 | CNY 26.4M | 0.01 | - |
| 2018 | CNY 187M | 0.08 | 148.2% |
| 2017 | CNY 264M | 0.12 | 85.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Jun 3, 2016.
Who owns Harbin Gloria Pharmaceuticals
- Insiders 9.80%
- Institutions 10.18%
- Public & others 80.02%
- Shares outstanding 2.23B
- Free float 1.95B
Harbin Gloria Pharmaceuticals company profile
- Company name
- Harbin Gloria Pharmaceuticals
- Ticker
- 002437.SHE
- ISIN
- CNE100000QG8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 23, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,350
- Fiscal year end
- December
- Address
- No. 29, Beijing Road, Harbin, China, 150025
- Phone
- 86 451 5735 1368
- Website
- gloria.cc
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride sustained-release tablets, sodium creatine phosphate for injection, ginkgo biloba extract injections, vitamins (B12), fluorouracil for injection, bleomycin hydrochloride for injection, and other injectable products, as well as pravastatin sodium tablets, olmesartan medoxomil amlodipine tablets, and edoxaban tosylate tablets. In addition, the company engages in pharmaceutical promotion; project investment; investment services; trade import and export; wholesale and retail; and technology promotion and application services. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is headquartered in Harbin, the People's Republic of China.
Harbin Gloria Pharmaceuticals management
6- Mr. Leifeng GuoGM, CFO & Director · born 1973
- Mr. Kang ZhouDeputy GM & Non-Independent Director · born 1984
- Ms. Yueyin LiuDeputy GM, Non-Independent Director & Secretary of the Board · born 1986
- Mr. Xiaohang WangDeputy General Manager · born 1979
- Mr. Runbao LiDeputy General Manager · born 1968
- Ms. Xiaojing ZhouAccounting Supervisor · born 1985